Showing results (131-140 of 201) with videos related to
Sort By:
Pageof 21
Bioorganic & Medicinal Chemistry Letters|June 28, 2017
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitorsChristopher M Yates, Edward P Garvey, Sammy R Shaver, et al.The Journal of Antimicrobial Chemotherapy|June 28, 2018
The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitisE P Garvey, A D Sharp, P A Warn, et al.Medical Mycology|April 3, 2024
Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598Kenan Gu, Robert Spitz, Erin Hammett, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 1994
Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory diseaseD L Hemsell, B B Little, S Faro, et al.Journal of Medicinal Chemistry|June 6, 1997
Substituted N-phenylisothioureas: potent inhibitors of human nitric oxide synthase with neuronal isoform selectivityB G Shearer, S Lee, J A Oplinger, et al.Antimicrobial Agents and Chemotherapy|January 22, 2015
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig modelE P Garvey, W J Hoekstra, W R Moore, et al.American Journal of Obstetrics and Gynecology|March 1, 1988
Comparison of cefotetan and cefoxitin prophylaxis for abdominal and vaginal hysterectomyA S Berkeley, K S Freedman, W J Ledger, et al.Antimicrobial Agents and Chemotherapy|March 15, 2017
Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in DogsLisa F Shubitz, Michael E Roy, Hien T Trinh, et al.Antimicrobial Agents and Chemotherapy|July 1, 2015
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasisE P Garvey, W J Hoekstra, R J Schotzinger, et al.BMC Endocrine Disorders|July 15, 2022
A systematic review of patient-reported outcome measures in paediatric endocrinologyRichard G McGee, Edward Y B Zhang, Jennifer J G Tan, et al.Pageof 21